Pipeline
Rights
Indications
- Metabolic Disease
- NASH/NAFLD
- IBD
- IPF
Seek approval for Phase 1 clinical trial in H2 2023
- Eosinophilic-Driven Asthma
- Atopic Dermatitis
Nominate preclinical candidate in H1 2023
- Insulin Resistance/Diabetes
Discovery Stage
(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-KCDTWFW'); window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-QYWG9MRT4K'); { "@context" : "http://schema.org", "@type" : "Organization", "url" : "https://liminal.miara.co.uk", "name" : "Liminal BioSciences", "sameAs" : [ "https://twitter.com/LiminalBio", "https://www.linkedin.com/company/liminal-biosciences-inc", "https://www.youtube.com/channel/UCrz1TGGazdWvsF8HfDMTlyg" ] }
Seek approval for Phase 1 clinical trial in H2 2023
Nominate preclinical candidate in H1 2023
Discovery Stage